Subcutaneous (SC) Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL): Dose-Escalation Data from a Phase I/II Trial

被引：0

作者：

Hutchings, Martin ^{[1
]}

Lugtenburg, Pieternella ^{[2
]}

Mous, Rogier ^{[3
]}

Clausen, Michael Roost ^{[4
]}

Chamuleau, Martine ^{[5
]}

Linton, Kim ^{[6
]}

Rule, Simon ^{[7
]}

Lopez, Juanita ^{[8
]}

Oliveri, Roberto S. ^{[9
]}

DeMarco, Dena ^{[10
]}

Elliott, Brian ^{[10
]}

Johnson, Peter ^{[11
]}

机构：

[1] Rigshosp, Copenhagen, Denmark

[2] Erasmus MC Canc Inst, Lunenburg Lymphoma Phase Consortium HOVON LLPC 1, Rotterdam, Netherlands

[3] Univ Med Ctr Utrecht, Lunenburg Lymphoma Phase Consortium HOVON LLPC 1, Utrecht, Netherlands

[4] Vejle Hosp, Vejle, Denmark

[5] Vrije Univ Amsterdam, Med Ctr, Lunenburg Lymphoma Phase Consortium HOVON LLPC 1, Amsterdam, Netherlands

[6] Christie Hosp, Manchester, Lancs, England

[7] Plymouth Univ, Med Sch, Plymouth, Devon, England

[8] Royal Marsden Hosp, London, England

[9] Genmab, Copenhagen, Denmark

[10] Genmab, Princeton, NJ USA

[11] Canc Res UK Ctr, Southampton, Hants, England

来源：

关键词：

antibody; B-cell lymphoma; BCL; immunotherapy; lymphoma;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ABCL-346

引用

页码：S274 / S274

页数：1